Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC

Mervat El Ansary; Sherif Mogawer; Samah Abd Elhamid; Sahr Alwakil; Fatma Aboelkasem; Hatem El Sabaawy; Olfat Abdelhalim

doi:10.1007/s00432-012-1298-8

Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC

Mervat El Ansary, Sherif Mogawer, Samah Abd Elhamid, Sahr Alwakil, Fatma Aboelkasem, Hatem El Sabaawy, Olfat Abdelhalim

Research output: Contribution to journal › Article › peer-review

60 Scopus citations

Abstract

Background: Dendritic cells (DCs) could be used as potential cellular adjuvant for the production of specific tumor vaccines. Objectives: Our study was aimed to evaluate the safety and efficacy of autologous pulsed DC vaccine in advanced hepatocellular carcinoma (HCC) patients in comparison with supportive treatment. Methods: Thirty patients with advanced HCC not suitable for radical or loco-regional therapies were enrolled. Patients were divided into 2 groups, group I consisted of 15 patients received I.D vaccination with mature autologous DCs pulsed ex vivo with a liver tumor cell line lysate. Group II (control group, no. 15) received supportive treatment. One hundred and 4 ml of venous blood were obtained from each patient to generate DCs. DCs were identified by CD80, CD83, CD86 and HLA-DR expressions using flow cytometry. Follow up at 3, and 6 months post injection by clinical, radiological and laboratory assessment was done. Results: Improvement in overall survival was observed. Partial radiological response was obtained in 2 patients (13.3 %), stable course in 9 patients (60 %) and 4 patients (26.7 %) showed progressive disease (died at 4 months post-injection). Both CD8⁺ T cells and serum interferon gamma were elevated after DCs injection. Conclusion: Autologous DC vaccination in advanced HCC patients is safe and well tolerate.

Original language	English (US)
Pages (from-to)	39-48
Number of pages	10
Journal	Journal of Cancer Research and Clinical Oncology
Volume	139
Issue number	1
DOIs	https://doi.org/10.1007/s00432-012-1298-8
State	Published - Jan 2013

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Keywords

Adjuvant immunotherapy
DCs
HCC

Access to Document

10.1007/s00432-012-1298-8

Fingerprint Dive into the research topics of 'Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC'. Together they form a unique fingerprint.

Cite this

@article{10d32ac8e6d14ccfa869a68042ffc64f,

title = "Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC",

abstract = "Background: Dendritic cells (DCs) could be used as potential cellular adjuvant for the production of specific tumor vaccines. Objectives: Our study was aimed to evaluate the safety and efficacy of autologous pulsed DC vaccine in advanced hepatocellular carcinoma (HCC) patients in comparison with supportive treatment. Methods: Thirty patients with advanced HCC not suitable for radical or loco-regional therapies were enrolled. Patients were divided into 2 groups, group I consisted of 15 patients received I.D vaccination with mature autologous DCs pulsed ex vivo with a liver tumor cell line lysate. Group II (control group, no. 15) received supportive treatment. One hundred and 4 ml of venous blood were obtained from each patient to generate DCs. DCs were identified by CD80, CD83, CD86 and HLA-DR expressions using flow cytometry. Follow up at 3, and 6 months post injection by clinical, radiological and laboratory assessment was done. Results: Improvement in overall survival was observed. Partial radiological response was obtained in 2 patients (13.3 %), stable course in 9 patients (60 %) and 4 patients (26.7 %) showed progressive disease (died at 4 months post-injection). Both CD8+ T cells and serum interferon gamma were elevated after DCs injection. Conclusion: Autologous DC vaccination in advanced HCC patients is safe and well tolerate.",

keywords = "Adjuvant immunotherapy, DCs, HCC",

author = "{El Ansary}, Mervat and Sherif Mogawer and Elhamid, {Samah Abd} and Sahr Alwakil and Fatma Aboelkasem and Sabaawy, {Hatem El} and Olfat Abdelhalim",

year = "2013",

month = jan,

doi = "10.1007/s00432-012-1298-8",

language = "English (US)",

volume = "139",

pages = "39--48",

journal = "Journal of Cancer Research and Clinical Oncology",

issn = "0171-5216",

publisher = "Springer Verlag",

number = "1",

}

TY - JOUR

T1 - Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC

AU - El Ansary, Mervat

AU - Mogawer, Sherif

AU - Elhamid, Samah Abd

AU - Alwakil, Sahr

AU - Aboelkasem, Fatma

AU - Sabaawy, Hatem El

AU - Abdelhalim, Olfat

PY - 2013/1

Y1 - 2013/1

N2 - Background: Dendritic cells (DCs) could be used as potential cellular adjuvant for the production of specific tumor vaccines. Objectives: Our study was aimed to evaluate the safety and efficacy of autologous pulsed DC vaccine in advanced hepatocellular carcinoma (HCC) patients in comparison with supportive treatment. Methods: Thirty patients with advanced HCC not suitable for radical or loco-regional therapies were enrolled. Patients were divided into 2 groups, group I consisted of 15 patients received I.D vaccination with mature autologous DCs pulsed ex vivo with a liver tumor cell line lysate. Group II (control group, no. 15) received supportive treatment. One hundred and 4 ml of venous blood were obtained from each patient to generate DCs. DCs were identified by CD80, CD83, CD86 and HLA-DR expressions using flow cytometry. Follow up at 3, and 6 months post injection by clinical, radiological and laboratory assessment was done. Results: Improvement in overall survival was observed. Partial radiological response was obtained in 2 patients (13.3 %), stable course in 9 patients (60 %) and 4 patients (26.7 %) showed progressive disease (died at 4 months post-injection). Both CD8+ T cells and serum interferon gamma were elevated after DCs injection. Conclusion: Autologous DC vaccination in advanced HCC patients is safe and well tolerate.

AB - Background: Dendritic cells (DCs) could be used as potential cellular adjuvant for the production of specific tumor vaccines. Objectives: Our study was aimed to evaluate the safety and efficacy of autologous pulsed DC vaccine in advanced hepatocellular carcinoma (HCC) patients in comparison with supportive treatment. Methods: Thirty patients with advanced HCC not suitable for radical or loco-regional therapies were enrolled. Patients were divided into 2 groups, group I consisted of 15 patients received I.D vaccination with mature autologous DCs pulsed ex vivo with a liver tumor cell line lysate. Group II (control group, no. 15) received supportive treatment. One hundred and 4 ml of venous blood were obtained from each patient to generate DCs. DCs were identified by CD80, CD83, CD86 and HLA-DR expressions using flow cytometry. Follow up at 3, and 6 months post injection by clinical, radiological and laboratory assessment was done. Results: Improvement in overall survival was observed. Partial radiological response was obtained in 2 patients (13.3 %), stable course in 9 patients (60 %) and 4 patients (26.7 %) showed progressive disease (died at 4 months post-injection). Both CD8+ T cells and serum interferon gamma were elevated after DCs injection. Conclusion: Autologous DC vaccination in advanced HCC patients is safe and well tolerate.

KW - Adjuvant immunotherapy

KW - DCs

KW - HCC

UR - http://www.scopus.com/inward/record.url?scp=84872297524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872297524&partnerID=8YFLogxK

U2 - 10.1007/s00432-012-1298-8

DO - 10.1007/s00432-012-1298-8

M3 - Article

C2 - 22886490

AN - SCOPUS:84872297524

VL - 139

SP - 39

EP - 48

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 1

ER -

Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Cite this